{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:55:20Z","timestamp":1792652120502,"version":"4.5.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03534-8","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:26:12Z","timestamp":1758875172000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Targeted and epigenetic therapies for acute myeloid leukemia treatment"],"prefix":"10.1007","volume":"16","author":[{"given":"Marzieh","family":"Shokoohi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobin","family":"Ghaderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Mokarami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homaira","family":"Arian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mohammadnabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arastoo","family":"Farokhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"3","key":"3534_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nrc.2016.3","volume":"16","author":"M Greaves","year":"2016","unstructured":"Greaves M. Leukaemia\u2019firsts\u2019 in cancer research and treatment. Nat Rev Cancer. 2016;16(3):163\u201372.","journal-title":"Nat Rev Cancer"},{"key":"3534_CR2","unstructured":"Adithya Chennamadhavuni VL, Shiva Kumar R, Mukkamalla A, Shimanovsky. Leukemia. 2025 (last updated January 2023)."},{"issue":"Suppl 4","key":"3534_CR3","first-page":"4","volume":"10","author":"NM Nix","year":"2019","unstructured":"Nix NM, Price A. Acute myeloid leukemia: an ever-changing disease. J Adv Practitioner Oncol. 2019;10(Suppl 4):4.","journal-title":"J Adv Practitioner Oncol"},{"issue":"3","key":"3534_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/jcm5030033","volume":"5","author":"JN Saultz","year":"2016","unstructured":"Saultz JN, Garzon R. Acute myeloid leukemia: a concise review. J Clin Med. 2016;5(3):33.","journal-title":"J Clin Med"},{"key":"3534_CR5","unstructured":"Longo DL. Harrisons principles of internal medicine. 2012."},{"issue":"11","key":"3534_CR6","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1038\/leu.2017.92","volume":"31","author":"S Kayser","year":"2017","unstructured":"Kayser S, et al. Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. Leukemia. 2017;31(11):2347\u201354.","journal-title":"Leukemia"},{"key":"3534_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1385\/SCR:1:3:197","volume":"1","author":"S Sell","year":"2005","unstructured":"Sell S. Leukemia: stem cells, maturation arrest, and differentiation therapy. Stem Cell Rev. 2005;1:197\u2013205.","journal-title":"Stem Cell Rev"},{"issue":"5","key":"3534_CR8","first-page":"508","volume":"2","author":"D Schnerch","year":"2012","unstructured":"Schnerch D, et al. Cell cycle control in acute myeloid leukemia. Am J Cancer Res. 2012;2(5):508.","journal-title":"Am J Cancer Res"},{"issue":"12","key":"3534_CR9","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.cellsig.2009.06.002","volume":"21","author":"K Masson","year":"2009","unstructured":"Masson K, R\u00f6nnstrand L. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal. 2009;21(12):1717\u201326.","journal-title":"Cell Signal"},{"issue":"12","key":"3534_CR10","first-page":"1911","volume":"10","author":"M Nakao","year":"1996","unstructured":"Nakao M, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10(12):1911\u20138.","journal-title":"Leukemia"},{"issue":"8","key":"3534_CR11","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","volume":"97","author":"Y Yamamoto","year":"2001","unstructured":"Yamamoto Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97(8):2434\u20139.","journal-title":"Blood"},{"issue":"3","key":"3534_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMoa041974","volume":"352","author":"B Falini","year":"2005","unstructured":"Falini B, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254\u201366.","journal-title":"N Engl J Med"},{"issue":"6","key":"3534_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722\u201331.","journal-title":"Blood"},{"issue":"25","key":"3534_CR14","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, et al. Durable remissions with Ivosidenib in IDH1-Mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386\u201398.","journal-title":"N Engl J Med"},{"issue":"21","key":"3534_CR15","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","volume":"375","author":"JS Welch","year":"2016","unstructured":"Welch JS, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375(21):2023\u201336.","journal-title":"N Engl J Med"},{"issue":"8","key":"3534_CR16","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/sj.leu.2404266","volume":"20","author":"HA Vu","year":"2006","unstructured":"Vu HA, et al. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia. 2006;20(8):1414\u201321.","journal-title":"Leukemia"},{"issue":"1","key":"3534_CR17","first-page":"29","volume":"3","author":"E Hatzimichael","year":"2013","unstructured":"Hatzimichael E, et al. Gene mutations and molecularly targeted therapies in acute myeloid leukemia. Am J Blood Res. 2013;3(1):29\u201351.","journal-title":"Am J Blood Res"},{"issue":"18","key":"3534_CR18","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728\u201340.","journal-title":"N Engl J Med"},{"issue":"23","key":"3534_CR19","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"3534_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11899-015-0253-6","volume":"10","author":"Y Tabe","year":"2015","unstructured":"Tabe Y, Konopleva M. Role of microenvironment in resistance to therapy in AML. Curr Hematol Malig Rep. 2015;10(2):96\u2013103.","journal-title":"Curr Hematol Malig Rep"},{"issue":"12","key":"3534_CR21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"3","key":"3534_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"1","key":"3534_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, et al. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Therapy. 2024;9(1):175.","journal-title":"Signal Transduct Target Therapy"},{"issue":"3","key":"3534_CR24","first-page":"311","volume":"77","author":"DE Gerber","year":"2008","unstructured":"Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Family Phys. 2008;77(3):311\u20139.","journal-title":"Am Family Phys"},{"key":"3534_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7603\/s40681-015-0019-4","volume":"5","author":"VV Padma","year":"2015","unstructured":"Padma VV. An overview of targeted cancer therapy. BioMedicine. 2015;5:1\u20136.","journal-title":"BioMedicine"},{"key":"3534_CR26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","volume":"834","author":"YT Lee","year":"2018","unstructured":"Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188\u201396.","journal-title":"Eur J Pharmacol"},{"issue":"5110","key":"3534_CR27","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.8493530","volume":"260","author":"RC Mulligan","year":"1993","unstructured":"Mulligan RC. The basic science of gene therapy. Science. 1993;260(5110):926\u201332.","journal-title":"Science"},{"issue":"5S","key":"3534_CR28","doi-asserted-by":"publisher","first-page":"656","DOI":"10.6004\/jnccn.2018.0050","volume":"16","author":"M Tallman","year":"2018","unstructured":"Tallman M. Prognostic significance of molecular markers and targeted regimens in the management of acute myeloid leukemia. J Natl Compr Canc Netw. 2018;16(5S):656\u20139.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"3534_CR29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","volume":"17","author":"MS Tallman","year":"2019","unstructured":"Tallman MS, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(6):721\u201349.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"3534_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward PS, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225\u201334.","journal-title":"Cancer Cell"},{"issue":"7390","key":"3534_CR31","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature10860","volume":"483","author":"C Lu","year":"2012","unstructured":"Lu C, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483(7390):474\u20138.","journal-title":"Nature"},{"issue":"13","key":"3534_CR32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/jnci\/djq187","volume":"102","author":"ZJ Reitman","year":"2010","unstructured":"Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102(13):932\u201341.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"3534_CR33","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1021\/acs.jmedchem.9b01423","volume":"63","author":"JA Caravella","year":"2020","unstructured":"Caravella JA, et al. Structure-Based design and identification of FT-2102 (Olutasidenib), a potent Mutant-Selective IDH1 inhibitor. J Med Chem. 2020;63(4):1612\u201323.","journal-title":"J Med Chem"},{"issue":"11","key":"3534_CR34","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/ajh.25238","volume":"93","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, et al. Glasdegib in combination with cytarabine and Daunorubicin in patients with AML or high-risk MDS: phase 2 study results. Am J Hematol. 2018;93(11):1301\u201310.","journal-title":"Am J Hematol"},{"issue":"13","key":"3534_CR35","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/blood.2020007233","volume":"137","author":"EM Stein","year":"2021","unstructured":"Stein EM, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021;137(13):1792\u2013803.","journal-title":"Blood"},{"issue":"3","key":"3534_CR36","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","volume":"34","author":"AI Antar","year":"2020","unstructured":"Antar AI, et al. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020;34(3):682\u201396.","journal-title":"Leukemia"},{"issue":"6","key":"3534_CR37","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","volume":"64","author":"Z Wang","year":"2021","unstructured":"Wang Z, et al. FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance. J Med Chem. 2021;64(6):2878\u2013900.","journal-title":"J Med Chem"},{"issue":"5","key":"3534_CR38","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454\u201364.","journal-title":"N Engl J Med"},{"issue":"3","key":"3534_CR39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11864-022-00952-6","volume":"23","author":"J Senapati","year":"2022","unstructured":"Senapati J, Kadia TM. Which FLT3 inhibitor for treatment of AML? Curr Treat Options Oncol. 2022;23(3):359\u201380.","journal-title":"Curr Treat Options Oncol"},{"key":"3534_CR40","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2147\/OTT.S384293","volume":"15","author":"M Tecik","year":"2022","unstructured":"Tecik M, Adan A. Therapeutic targeting of FLT3 in acute myeloid leukemia: current status and novel approaches. Onco Targets Ther. 2022;15:1449\u201378.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"3534_CR41","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12964-024-01729-0","volume":"22","author":"C Hu","year":"2024","unstructured":"Hu C, et al. Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia. Cell Communication Signal. 2024;22(1):355.","journal-title":"Cell Communication Signal"},{"issue":"6","key":"3534_CR42","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1158\/0008-5472.CAN-23-1534","volume":"84","author":"P Wang","year":"2024","unstructured":"Wang P, et al. Foretinib is effective in acute myeloid leukemia by inhibiting FLT3 and overcoming secondary mutations that drive resistance to Quizartinib and gilteritinib. Cancer Res. 2024;84(6):905\u201318.","journal-title":"Cancer Res"},{"issue":"9","key":"3534_CR43","doi-asserted-by":"publisher","first-page":"7197","DOI":"10.1021\/acs.jmedchem.4c00051","volume":"67","author":"J Wang","year":"2024","unstructured":"Wang J, et al. Discovery of a novel orally bioavailable FLT3-PROTAC degrader for efficient treatment of acute myeloid leukemia and overcoming resistance of FLT3 inhibitors. J Med Chem. 2024;67(9):7197\u2013223.","journal-title":"J Med Chem"},{"issue":"6","key":"3534_CR44","doi-asserted-by":"publisher","first-page":"6877","DOI":"10.1002\/cam4.5480","volume":"12","author":"X Fei","year":"2023","unstructured":"Fei X, et al. FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta-analysis. Cancer Med. 2023;12(6):6877\u201388.","journal-title":"Cancer Med"},{"issue":"20","key":"3534_CR45","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.3390\/cancers15204957","volume":"15","author":"J Xu","year":"2023","unstructured":"Xu J, et al. Current advances and future strategies for BCL-2 inhibitors: potent weapons against cancers. Cancers. 2023;15(20):4957.","journal-title":"Cancers"},{"issue":"2","key":"3534_CR46","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.htct.2018.09.001","volume":"41","author":"EdV Campos","year":"2019","unstructured":"Campos EdV, Pinto R. Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia. Hematol Transfus Cell Therapy. 2019;41(2):169\u201377.","journal-title":"Hematol Transfus Cell Therapy"},{"issue":"20","key":"3534_CR47","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.3390\/cancers15204957","volume":"15","author":"J Xu","year":"2023","unstructured":"Xu J, et al. Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers. Cancers (Basel). 2023;15(20):4957.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"3534_CR48","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41375-023-01833-z","volume":"37","author":"LD Boila","year":"2023","unstructured":"Boila LD, et al. KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 Inhibition. Leukemia. 2023;37(4):751\u201364.","journal-title":"Leukemia"},{"issue":"1","key":"3534_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41408-023-00830-w","volume":"13","author":"BZ Carter","year":"2023","unstructured":"Carter BZ, et al. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023;13(1):57.","journal-title":"Blood Cancer J"},{"issue":"1","key":"3534_CR50","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/cancers17010142","volume":"17","author":"P Niscola","year":"2025","unstructured":"Niscola P, et al. Menin inhibitors: new targeted therapies for specific genetic subtypes of Difficult-to-Treat acute leukemias. Cancers. 2025;17(1):142.","journal-title":"Cancers"},{"issue":"5311","key":"3534_CR51","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1126\/science.276.5311.404","volume":"276","author":"SC Chandrasekharappa","year":"1997","unstructured":"Chandrasekharappa SC, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404\u20137.","journal-title":"Science"},{"issue":"7","key":"3534_CR52","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/6.7.1177","volume":"6","author":"I Lemmens","year":"1997","unstructured":"Lemmens I, et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. Hum Mol Genet. 1997;6(7):1177\u201383.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"3534_CR53","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrc2253","volume":"7","author":"AV Krivtsov","year":"2007","unstructured":"Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823\u201333.","journal-title":"Nat Rev Cancer"},{"key":"3534_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01057-7","volume":"14","author":"X Li","year":"2021","unstructured":"Li X, Song Y. Structure, function and inhibition of critical protein\u2013protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins. J Hematol Oncol. 2021;14:1\u201333.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"3534_CR55","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1038\/s41375-022-01707-w","volume":"36","author":"W Fiskus","year":"2022","unstructured":"Fiskus W, et al. Activity of Menin inhibitor Ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia. 2022;36(11):2729\u201333.","journal-title":"Leukemia"},{"issue":"1","key":"3534_CR56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-024-01632-8","volume":"17","author":"KV Nadiminti","year":"2024","unstructured":"Nadiminti KV, Sahasrabudhe KD, Liu H. Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead. J Hematol Oncol. 2024;17(1):113.","journal-title":"J Hematol Oncol"},{"issue":"7954","key":"3534_CR57","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, et al. The Menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920\u20134.","journal-title":"Nature"},{"issue":"7","key":"3534_CR58","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/17501911.2025.2485019","volume":"17","author":"MR Brown","year":"2025","unstructured":"Brown MR, Soto-Feliciano YM. Menin: from molecular insights to clinical impact. Epigenomics. 2025;17(7):489\u2013505.","journal-title":"Epigenomics"},{"issue":"7954","key":"3534_CR59","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner F, et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023;615(7954):913\u20139.","journal-title":"Nature"},{"issue":"1","key":"3534_CR60","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","volume":"12","author":"W Fiskus","year":"2022","unstructured":"Fiskus W, et al. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood cancer J. 2022;12(1):5.","journal-title":"Blood cancer J"},{"issue":"10","key":"3534_CR61","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.3324\/haematol.2022.282160","volume":"108","author":"J Rausch","year":"2023","unstructured":"Rausch J, et al. Menin inhibitor Ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax. Haematologica. 2023;108(10):2837.","journal-title":"Haematologica"},{"issue":"7","key":"3534_CR62","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMra1112635","volume":"367","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med. 2012;367(7):647\u201357.","journal-title":"N Engl J Med"},{"key":"3534_CR63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fonc.2018.00041","volume":"8","author":"Y Sun","year":"2018","unstructured":"Sun Y, Chen B-R, Deshpande A. Epigenetic regulators in the development, maintenance, and therapeutic targeting of acute myeloid leukemia. Front Oncol. 2018;8:41.","journal-title":"Front Oncol"},{"issue":"5","key":"3534_CR64","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"12","key":"3534_CR65","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079\u201389.","journal-title":"N Engl J Med"},{"issue":"7728","key":"3534_CR66","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526\u201331.","journal-title":"Nature"},{"issue":"22","key":"3534_CR67","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"CGAR Network","year":"2013","unstructured":"Network CGAR. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374.","journal-title":"N Engl J Med"},{"issue":"6330","key":"3534_CR68","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1126\/science.aam7304","volume":"355","author":"MA Dawson","year":"2017","unstructured":"Dawson MA. The cancer epigenome: concepts, challenges, and therapeutic opportunities. Science. 2017;355(6330):1147\u201352.","journal-title":"Science"},{"issue":"1","key":"3534_CR69","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5045\/br.2020.55.1.10","volume":"55","author":"E Fathi","year":"2020","unstructured":"Fathi E, et al. A general view of CD33\u2009+\u2009leukemic stem cells and CAR-T cells as interesting targets in acute myeloblatsic leukemia therapy. Blood Res. 2020;55(1):10.","journal-title":"Blood Res"},{"issue":"7","key":"3534_CR70","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1200\/JCO.2011.39.2092","volume":"30","author":"G Marcucci","year":"2012","unstructured":"Marcucci G, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30(7):742\u201350.","journal-title":"J Clin Oncol"},{"issue":"10","key":"3534_CR71","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1200\/JCO.2010.32.7742","volume":"29","author":"KH Metzeler","year":"2011","unstructured":"Metzeler KH, et al. TET2 mutations improve the new European leukemiaNet risk classification of acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2011;29(10):1373\u201381.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3534_CR72","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12\u201327.","journal-title":"Cell"},{"issue":"10","key":"3534_CR73","doi-asserted-by":"publisher","first-page":"e1006193","DOI":"10.1371\/journal.pgen.1006193","volume":"12","author":"M Stahl","year":"2016","unstructured":"Stahl M, et al. Epigenetics in cancer: a hematological perspective. PLoS Genet. 2016;12(10):e1006193.","journal-title":"PLoS Genet"},{"key":"3534_CR74","unstructured":"Kim TK, Gore SD, Zeidan AM. Epigenetic therapy in acute myeloid leukemia: current and future directions. In: Seminars in hematology. Elsevier; 2015."},{"issue":"2","key":"3534_CR75","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/MOH.0000000000000636","volume":"28","author":"E Yankova","year":"2021","unstructured":"Yankova E, Aspris D, Tzelepis K. The N6-methyladenosine RNA modification in acute myeloid leukemia. Curr Opin Hematol. 2021;28(2):80\u20135.","journal-title":"Curr Opin Hematol"},{"issue":"11","key":"3534_CR76","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/nm.4416","volume":"23","author":"LP Vu","year":"2017","unstructured":"Vu LP, et al. The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 2017;23(11):1369\u201376.","journal-title":"Nat Med"},{"issue":"1","key":"3534_CR77","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.stem.2020.04.001","volume":"27","author":"J Wang","year":"2020","unstructured":"Wang J, et al. Leukemogenic chromatin alterations promote AML leukemia stem cells via a KDM4C-ALKBH5-AXL signaling axis. Cell Stem Cell. 2020;27(1):81\u2013e978.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"3534_CR78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.stem.2022.12.003","volume":"30","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, et al. Decoding m(6)A RNA methylome identifies PRMT6-regulated lipid transport promoting AML stem cell maintenance. Cell Stem Cell. 2023;30(1):69\u2013e857.","journal-title":"Cell Stem Cell"},{"issue":"7683","key":"3534_CR79","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nature24678","volume":"552","author":"I Barbieri","year":"2017","unstructured":"Barbieri I, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature. 2017;552(7683):126\u201331.","journal-title":"Nature"},{"issue":"1","key":"3534_CR80","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ccell.2016.11.017","volume":"31","author":"Z Li","year":"2017","unstructured":"Li Z, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N(6)-Methyladenosine RNA demethylase. Cancer Cell. 2017;31(1):127\u201341.","journal-title":"Cancer Cell"},{"issue":"4","key":"3534_CR81","doi-asserted-by":"publisher","first-page":"e00206","DOI":"10.1097\/BS9.0000000000000206","volume":"6","author":"S Yao","year":"2024","unstructured":"Yao S, et al. Epigenetic modifications in hematopoietic ecosystem: a key tuner from homeostasis to acute myeloid leukemia. Blood Sci. 2024;6(4):e00206.","journal-title":"Blood Sci"},{"issue":"3","key":"3534_CR82","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, et al. Efficacy of Azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223\u201332.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3534_CR83","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","volume":"28","author":"AF Cashen","year":"2010","unstructured":"Cashen AF, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556\u201361.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3534_CR84","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1080\/10428194.2016.1228927","volume":"58","author":"B Ball","year":"2017","unstructured":"Ball B, et al. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. Leuk Lymphoma. 2017;58(5):1022\u201336.","journal-title":"Leuk Lymphoma"},{"key":"3534_CR85","doi-asserted-by":"publisher","first-page":"204062071881669","DOI":"10.1177\/2040620718816698","volume":"10","author":"JP Bewersdorf","year":"2019","unstructured":"Bewersdorf JP, et al. Epigenetic therapy combinations in acute myeloid leukemia: what are the options? Therapeutic Adv Hematol. 2019;10:2040620718816698.","journal-title":"Therapeutic Adv Hematol"},{"issue":"1","key":"3534_CR86","first-page":"42","volume":"127","author":"BJ Wouters","year":"2016","unstructured":"Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood. J Am Soc Hematol. 2016;127(1):42\u201352.","journal-title":"J Am Soc Hematol"},{"issue":"2","key":"3534_CR87","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/leu.2016.182","volume":"31","author":"E Donato","year":"2017","unstructured":"Donato E, et al. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors. Leukemia. 2017;31(2):479\u201390.","journal-title":"Leukemia"},{"issue":"13","key":"3534_CR88","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","volume":"130","author":"E Jabbour","year":"2017","unstructured":"Jabbour E, et al. Randomized phase 2 study of low-dose decitabine vs low-dose Azacitidine in lower-risk MDS and MDS\/MPN. Blood. 2017;130(13):1514\u201322.","journal-title":"Blood"},{"issue":"18","key":"3534_CR89","first-page":"2834","volume":"124","author":"M Krevvata","year":"2014","unstructured":"Krevvata M, et al. Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. Blood. J Am Soc Hematol. 2014;124(18):2834\u201346.","journal-title":"J Am Soc Hematol"},{"issue":"1","key":"3534_CR90","first-page":"48","volume":"130","author":"CC Smith","year":"2017","unstructured":"Smith CC, et al. Heterogeneous resistance to Quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood J Am Soc Hematol. 2017;130(1):48\u201358.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"3534_CR91","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"H Liu","year":"2021","unstructured":"Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021;14(1):49.","journal-title":"J Hematol Oncol"},{"issue":"24","key":"3534_CR92","first-page":"2137","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood J Am Soc Hematol. 2020;135(24):2137\u201345.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"3534_CR93","first-page":"7","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. J Am Soc Hematol. 2019;133(1):7\u201317.","journal-title":"J Am Soc Hematol"},{"issue":"4","key":"3534_CR94","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3390\/cancers13040748","volume":"13","author":"H Pasquer","year":"2021","unstructured":"Pasquer H, et al. Descriptive and functional genomics in acute myeloid leukemia (AML): paving the road for a cure. Cancers. 2021;13(4):748.","journal-title":"Cancers"},{"issue":"24","key":"3534_CR95","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1182\/bloodadvances.2017009829","volume":"1","author":"AE Perl","year":"2017","unstructured":"Perl AE. The role of targeted therapy in the management of patients with AML. Blood Adv. 2017;1(24):2281\u201394.","journal-title":"Blood Adv"},{"key":"3534_CR96","doi-asserted-by":"publisher","first-page":"e390018","DOI":"10.1200\/EDBK_390018","volume":"43","author":"C Lai","year":"2023","unstructured":"Lai C, et al. Older adults with newly diagnosed AML: hot topics for the practicing clinician. Am Soc Clin Oncol Educational Book. 2023;43:e390018.","journal-title":"Am Soc Clin Oncol Educational Book"},{"issue":"6","key":"3534_CR97","first-page":"722","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood J Am Soc Hematol. 2017;130(6):722\u201331.","journal-title":"Blood J Am Soc Hematol"},{"issue":"4","key":"3534_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtct.2022.12.006","volume":"29","author":"AE Perl","year":"2023","unstructured":"Perl AE, et al. Outcomes in patients with FLT3-mutated relapsed\/refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy. Transplant cell Ther. 2023;29(4):1\u2013265.","journal-title":"Transplant cell Ther"},{"issue":"7","key":"3534_CR99","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"key":"3534_CR100","doi-asserted-by":"publisher","first-page":"172641","DOI":"10.1016\/j.ejphar.2019.172641","volume":"862","author":"A Shimada","year":"2019","unstructured":"Shimada A. Hematological malignancies and molecular targeting therapy. Eur J Pharmacol. 2019;862:172641.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"3534_CR101","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","volume":"16","author":"M Larrosa-Garcia","year":"2017","unstructured":"Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: current status and future directions. Mol Cancer Ther. 2017;16(6):991\u20131001.","journal-title":"Mol Cancer Ther"},{"key":"3534_CR102","doi-asserted-by":"publisher","first-page":"896426","DOI":"10.3389\/fonc.2022.896426","volume":"12","author":"J Niu","year":"2022","unstructured":"Niu J, Peng D, Liu L. Drug resistance mechanisms of acute myeloid leukemia stem cells. Front Oncol. 2022;12:896426.","journal-title":"Front Oncol"},{"issue":"4","key":"3534_CR103","first-page":"409","volume":"21","author":"J Ma","year":"2021","unstructured":"Ma J, Ge Z. Recent advances of targeted therapy in relapsed\/refractory acute myeloid leukemia. Bosn J Basic Med Sci. 2021;21(4):409.","journal-title":"Bosn J Basic Med Sci"},{"issue":"20","key":"3534_CR104","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","volume":"29","author":"C R\u00f6llig","year":"2011","unstructured":"R\u00f6llig C, et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011;29(20):2758\u201365.","journal-title":"J Clin Oncol"},{"issue":"6481","key":"3534_CR105","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365.","journal-title":"Science"},{"issue":"6","key":"3534_CR106","doi-asserted-by":"publisher","first-page":"567","DOI":"10.33263\/BRIAC136.567","volume":"13","author":"K Hadipour","year":"2023","unstructured":"Hadipour K, et al. A comparative review on genome editing approaches. Biointerface Res Appl Chem. 2023;13(6):567.","journal-title":"Biointerface Res Appl Chem"},{"issue":"5","key":"3534_CR107","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.stem.2017.10.010","volume":"21","author":"RA Morgan","year":"2017","unstructured":"Morgan RA, et al. Hematopoietic stem cell gene therapy: progress and lessons learned. Cell Stem Cell. 2017;21(5):574\u201390.","journal-title":"Cell Stem Cell"},{"key":"3534_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-020-00196-2","volume":"8","author":"J Yu","year":"2020","unstructured":"Yu J, et al. Advances in targeted therapy for acute myeloid leukemia. Biomark Res. 2020;8:1\u201311.","journal-title":"Biomark Res"},{"issue":"7714","key":"3534_CR109","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","volume":"559","author":"TL Roth","year":"2018","unstructured":"Roth TL, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018;559(7714):405\u20139.","journal-title":"Nature"},{"issue":"13","key":"3534_CR110","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","volume":"381","author":"L Xu","year":"2019","unstructured":"Xu L, et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N Engl J Med. 2019;381(13):1240\u20137.","journal-title":"N Engl J Med"},{"key":"3534_CR111","doi-asserted-by":"crossref","unstructured":"Mohammadhassan R et al. The prominent characteristics of the effective sgRNA for a precise CRISPR genome editing, in CRISPR Technology-Recent Advances. 2022, IntechOpen.","DOI":"10.5772\/intechopen.106711"},{"issue":"18","key":"3534_CR112","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1158\/1078-0432.CCR-22-1618","volume":"28","author":"P Jin","year":"2022","unstructured":"Jin P, et al. Large-scale in vitro and in vivo CRISPR-Cas9 knockout screens identify a 16-gene fitness score for improved risk assessment in acute myeloid leukemia. Clin Cancer Res. 2022;28(18):4033\u201344.","journal-title":"Clin Cancer Res"},{"key":"3534_CR113","doi-asserted-by":"publisher","DOI":"10.59094\/emsj.v57i1.90","author":"R Mohammadhassan","year":"2022","unstructured":"Mohammadhassan R, Ebli PE, Behrouz MA. CRISPR technology for diagnosis: A Brief Review: CRISPR for Diagnosis. Everyman\u2019s Sci. 2022;57(1). https:\/\/doi.org\/10.59094\/emsj.v57i1.90.","journal-title":"Everyman's Sci"},{"issue":"1","key":"3534_CR114","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01884-x","volume":"16","author":"M Shokoohi","year":"2025","unstructured":"Shokoohi M, et al. Genetic advancements in breast cancer treatment: a review. Discover Oncol. 2025;16(1):127.","journal-title":"Discover Oncol"},{"issue":"11","key":"3534_CR115","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1007\/s11864-023-01140-w","volume":"24","author":"S Guo","year":"2023","unstructured":"Guo S, et al. Developing strategies to improve the efficacy of CAR-T therapy for acute myeloid leukemia. Curr Treat Options Oncol. 2023;24(11):1614\u201332.","journal-title":"Curr Treat Options Oncol"},{"issue":"11","key":"3534_CR116","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.stem.2024.09.003","volume":"31","author":"R-J Ji","year":"2024","unstructured":"Ji R-J, et al. Epitope prime editing shields hematopoietic cells from CD123 immunotherapy for acute myeloid leukemia. Cell Stem Cell. 2024;31(11):1650\u201366. e8.","journal-title":"Cell Stem Cell"},{"key":"3534_CR117","doi-asserted-by":"crossref","unstructured":"Lydeard JR, et al. Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity. Molecular Therapy Methods & Clinical Development; 2023. p. 31.","DOI":"10.1016\/j.omtm.2023.101167"},{"issue":"2","key":"3534_CR118","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.1016\/j.jtct.2023.12.311","volume":"30","author":"JF DiPersio","year":"2024","unstructured":"DiPersio JF, et al. Trem-Cel, a CRISPR\/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT).. Transplant Cell Ther. 2024;30(2):S237\u20138.","journal-title":"Transplant Cell Ther"},{"issue":"Supplement 1","key":"3534_CR119","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1182\/blood-2022-170201","volume":"140","author":"S Naik","year":"2022","unstructured":"Naik S, et al. Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial. Blood. 2022;140(Supplement 1):4584\u20135.","journal-title":"Blood"},{"key":"3534_CR120","first-page":"56","volume":"30","author":"CF Magnani","year":"2023","unstructured":"Magnani CF, et al. Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells. Mol Ther. 2023;30:56\u201371.","journal-title":"Mol Ther"},{"key":"3534_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-021-00275-y","volume":"9","author":"C Liang","year":"2021","unstructured":"Liang C, et al. TOX as a potential target for immunotherapy in lymphocytic malignancies. Biomark Res. 2021;9:1\u20138.","journal-title":"Biomark Res"},{"key":"3534_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.622509","volume":"11","author":"W Jiang","year":"2021","unstructured":"Jiang W, et al. Exhausted CD8\u2009+\u2009T cells in the tumor immune microenvironment: new pathways to therapy. Front Immunol. 2021;11:622509.","journal-title":"Front Immunol"},{"issue":"7786","key":"3534_CR123","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn RC, et al. C-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576(7786):293\u2013300.","journal-title":"Nature"},{"issue":"7749","key":"3534_CR124","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen J, et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 2019;567(7749):530\u20134.","journal-title":"Nature"},{"issue":"1","key":"3534_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03797-7","volume":"20","author":"Y Lu","year":"2022","unstructured":"Lu Y, et al. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R\/R-AML). J Transl Med. 2022;20(1):600.","journal-title":"J Transl Med"},{"key":"3534_CR126","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179086","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. Naturally selected CD7-targeted chimeric antigen receptor (CAR)-T cell therapy for refractory\/relapsed acute myeloid leukemia: phase i clinical trial. Blood. 2023. https:\/\/doi.org\/10.1182\/blood-2023-179086.","journal-title":"Blood"},{"key":"3534_CR127","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.1182\/blood-2024-207197","volume":"144","author":"J Yin","year":"2024","unstructured":"Yin J, et al. Unleashing the power of CD19 CAR-T in relapsed AML: findings from a prospective single-center clinical trial. Blood. 2024;144:4836.","journal-title":"Blood"},{"key":"3534_CR128","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180990","author":"NN Shah","year":"2023","unstructured":"Shah NN, et al. Phase 1\/2 study of donor-derived anti-cD33 chimeric antigen receptor expressing t cells (vcAR33) in patients with relapsed or refractory acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Blood. 2023. https:\/\/doi.org\/10.1182\/blood-2023-180990.","journal-title":"Blood"},{"issue":"4","key":"3534_CR129","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008174","volume":"12","author":"VL Presti","year":"2024","unstructured":"Presti VL, et al. Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML. J Immunother Cancer. 2024;12(4):e008174.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"3534_CR130","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2109167","volume":"386","author":"S Goyal","year":"2022","unstructured":"Goyal S, et al. Acute myeloid leukemia case after gene therapy for sickle cell disease. N Engl J Med. 2022;386(2):138\u201347.","journal-title":"N Engl J Med"},{"key":"3534_CR131","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/BF02987765","volume":"10","author":"S Einhorn","year":"1993","unstructured":"Einhorn S, Strander H. Interferon treatment of human malignancies-a short review. Medical Oncology and Tumor Pharmacotherapy. 1993;10:25\u20139.","journal-title":"Medical Oncology and Tumor Pharmacotherapy"},{"issue":"4","key":"3534_CR132","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0167-5699(95)80116-2","volume":"16","author":"GD Schmidt-Wolf","year":"1995","unstructured":"Schmidt-Wolf GD, Schmidt-Wolf IG. Cytokines and gene therapy. Immunol Today. 1995;16(4):173\u20135.","journal-title":"Immunol Today"},{"issue":"1","key":"3534_CR133","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.gt.3300560","volume":"5","author":"S Finke","year":"1998","unstructured":"Finke S, et al. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3\u2009+\u2009CD56\u2009+\u2009immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Ther. 1998;5(1):31\u20139.","journal-title":"Gene Ther"},{"issue":"10","key":"3534_CR134","first-page":"3138","volume":"97","author":"M Notter","year":"2001","unstructured":"Notter M, et al. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Blood. J Am Soc Hematol. 2001;97(10):3138\u201345.","journal-title":"J Am Soc Hematol"},{"issue":"5","key":"3534_CR135","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1172\/JCI1472","volume":"101","author":"K Kato","year":"1998","unstructured":"Kato K, et al. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest. 1998;101(5):1133\u201341.","journal-title":"J Clin Invest"},{"issue":"12","key":"3534_CR136","first-page":"4948","volume":"42","author":"E Borden","year":"1982","unstructured":"Borden E, Hogan T, Voelkel J. Comparative antiproliferative activity in vitro of natural interferons \u03b1 and \u03b2 for diploid and transformed human cells. Cancer Res. 1982;42(12):4948\u201353.","journal-title":"Cancer Res"},{"issue":"1","key":"3534_CR137","first-page":"8034038","volume":"2022","author":"S Tutunchi","year":"2022","unstructured":"Tutunchi S, et al. Association between the expression levels of MicroRNA-101,\u2010103, and\u201029a with autotaxin and lysophosphatidic acid receptor 2 expression in gastric cancer patients. J Oncol. 2022;2022(1):8034038.","journal-title":"J Oncol"},{"key":"3534_CR138","first-page":"1","volume-title":"Loc646329 sponges miR-21 to reduce RAS\/MAP kinase signaling pathway in oral squamous cell carcinoma (OSCC)","author":"A Adereh","year":"2024","unstructured":"Adereh A, et al. Loc646329 sponges miR-21 to reduce RAS\/MAP kinase signaling pathway in oral squamous cell carcinoma (OSCC). Naunyn-Schmiedeberg\u2019s Archives of Pharmacology; 2024. p. 1\u20139."},{"key":"3534_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-0556-2-1","volume":"2","author":"F Schakowski","year":"2004","unstructured":"Schakowski F, et al. Novel non-viral method for transfection of primary leukemia cells and cell lines. Genetic Vaccines Therapy. 2004;2:1\u201311.","journal-title":"Genetic Vaccines Therapy"},{"issue":"1","key":"3534_CR140","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S1079-9796(03)00062-7","volume":"31","author":"R Stripecke","year":"2003","unstructured":"Stripecke R, et al. The use of lentiviral vectors in gene therapy of leukemia: combinatorial gene delivery of immunomodulators into leukemia cells by state-of-the-art vectors. Blood Cells Mol Dis. 2003;31(1):28\u201337.","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"3534_CR141","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/mccm.6.3.127.134","volume":"6","author":"PH Roddie","year":"2000","unstructured":"Roddie PH, Paterson T, Turner ML. Gene transfer to primary acute myeloid leukaemia blasts and myeloid leukaemia cell lines. Cytokines, Cellular & Molecular Therapy. 2000;6(3):127\u201334.","journal-title":"Cytokines, Cellular & Molecular Therapy"},{"issue":"5","key":"3534_CR142","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/hum.2005.16.541","volume":"16","author":"BJ Carter","year":"2005","unstructured":"Carter BJ. Adeno-associated virus vectors in clinical trials. Hum Gene Ther. 2005;16(5):541\u201350.","journal-title":"Hum Gene Ther"},{"key":"3534_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422X-4-99","volume":"4","author":"Rd Coura","year":"2007","unstructured":"Coura Rd, Nardi NB. The state of the art of adeno-associated virus-based vectors in gene therapy. Virol J. 2007;4:1\u20137.","journal-title":"Virol J"},{"issue":"1","key":"3534_CR144","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/sj.gt.3302364","volume":"11","author":"N Bessis","year":"2004","unstructured":"Bessis N, GarciaCozar F, Boissier M. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 2004;11(1):S10-7.","journal-title":"Gene Ther"},{"issue":"16","key":"3534_CR145","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1089\/104303403322495061","volume":"14","author":"K Bupp","year":"2003","unstructured":"Bupp K, Roth MJ. Targeting a retroviral vector in the absence of a known cell-targeting ligand. Hum Gene Ther. 2003;14(16):1557\u201364.","journal-title":"Hum Gene Ther"},{"issue":"11","key":"3534_CR146","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/sj.gt.3302467","volume":"12","author":"I Hartl","year":"2005","unstructured":"Hartl I, et al. Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells. Gene Ther. 2005;12(11):918\u201326.","journal-title":"Gene Ther"},{"issue":"2","key":"3534_CR147","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0042-6822(03)00529-4","volume":"315","author":"PD Khare","year":"2003","unstructured":"Khare PD, Russell SJ, Federspiel MJ. Avian leukosis virus is a versatile eukaryotic platform for polypeptide display. Virology. 2003;315(2):303\u201312.","journal-title":"Virology"},{"issue":"11","key":"3534_CR148","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/jgm.967","volume":"8","author":"DA Waterkamp","year":"2006","unstructured":"Waterkamp DA, et al. Isolation of targeted AAV2 vectors from novel virus display libraries. J Gene Med. 2006;8(11):1307\u201319.","journal-title":"J Gene Med"},{"issue":"4","key":"3534_CR149","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.beha.2008.08.003","volume":"21","author":"S Grant","year":"2008","unstructured":"Grant S. Is the focus moving toward a combination of targeted drugs? Best Pract Res Clin Haematol. 2008;21(4):629\u201337.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"3534_CR150","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1586\/ehm.12.43","volume":"5","author":"P Bose","year":"2012","unstructured":"Bose P, Grant S. Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia? Expert Rev Hematol. 2012;5(5):475\u20138.","journal-title":"Expert Rev Hematol"},{"key":"3534_CR151","doi-asserted-by":"publisher","DOI":"10.1126\/science.331.6024.1542","volume-title":"Combining targeted drugs to stop resistant tumors","author":"J Kaiser","year":"2011","unstructured":"Kaiser J. Combining targeted drugs to stop resistant tumors. American Association for the Advancement of Science; 2011. https:\/\/doi.org\/10.1126\/science.331.6024.1542."},{"issue":"10","key":"3534_CR152","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","volume":"11","author":"SB Baylin","year":"2011","unstructured":"Baylin SB, Jones PA. A decade of exploring the cancer epigenome\u2014biological and translational implications. Nat Rev Cancer. 2011;11(10):726\u201334.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"3534_CR153","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","volume":"128","author":"PA Jones","year":"2007","unstructured":"Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683\u201392.","journal-title":"Cell"},{"issue":"25","key":"3534_CR154","doi-asserted-by":"publisher","first-page":"6025","DOI":"10.1182\/blood-2012-03-413898","volume":"119","author":"W Blum","year":"2012","unstructured":"Blum W, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 2012;119(25):6025\u201331.","journal-title":"Blood"},{"issue":"5","key":"3534_CR155","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1535-7163.MCT-13-0770","volume":"13","author":"W Fiskus","year":"2014","unstructured":"Fiskus W, et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther. 2014;13(5):1142\u201354.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"3534_CR156","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1200\/JCO.2010.30.2554","volume":"29","author":"G Marcucci","year":"2011","unstructured":"Marcucci G, Haferlach T, D\u00f6hner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475\u201386.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3534_CR157","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","volume":"361","author":"ER Mardis","year":"2009","unstructured":"Mardis ER, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058\u201366.","journal-title":"N Engl J Med"},{"issue":"25","key":"3534_CR158","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424\u201333.","journal-title":"N Engl J Med"},{"issue":"22","key":"3534_CR159","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","volume":"360","author":"F Delhommeau","year":"2009","unstructured":"Delhommeau F, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289\u2013301.","journal-title":"N Engl J Med"},{"key":"3534_CR160","doi-asserted-by":"publisher","DOI":"10.17116\/patol20238504124","author":"D Baram","year":"2023","unstructured":"Baram D, et al. WHO classification of tumors of hematopoietic and lymphoid tissues, 2022 (5th edition): lymphoid tumors.. Arkhiv patologii. 2023. https:\/\/doi.org\/10.17116\/patol20238504124.","journal-title":"Arkhiv patologii"},{"issue":"3","key":"3534_CR161","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner H, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453\u201374.","journal-title":"Blood"},{"issue":"6","key":"3534_CR162","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/17474086.2018.1475225","volume":"11","author":"G Visani","year":"2018","unstructured":"Visani G, et al. Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome. Expert Rev Hematol. 2018;11(6):455\u201361.","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"3534_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29382","volume":"10","author":"T Lin","year":"2024","unstructured":"Lin T, et al. CRISPR screens in mechanism and target discovery for AML. Heliyon. 2024;10(8):e29382.","journal-title":"Heliyon"},{"key":"3534_CR164","doi-asserted-by":"crossref","unstructured":"Lee D. Synergistic CRISPR\/Cas9 gene editing and CAR T-cell therapy for FLT3-Mutated in AML. J Student Res, 2024. 13.","DOI":"10.47611\/jsrhs.v13i1.6131"},{"issue":"1","key":"3534_CR165","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s10020-025-01085-w","volume":"31","author":"Z Khosroabadi","year":"2025","unstructured":"Khosroabadi Z, et al. Single cell RNA sequencing improves the next generation of approaches to AML treatment: challenges and perspectives. Mol Med. 2025;31(1):33.","journal-title":"Mol Med"},{"key":"3534_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101135","volume":"31","author":"JR Lydeard","year":"2023","unstructured":"Lydeard JR, et al. Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity. Mol Ther Methods Clin Dev. 2023;31:101135.","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03534-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03534-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03534-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:03:06Z","timestamp":1758880986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03534-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":166,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3534"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03534-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"\u00a0Competing interests"}}],"article-number":"1711"}}